newsfilter
← Latest News
GlobeNewswire·

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (NASDAQ:BNTX, "BioNTech")) and DualityBiologics (Suzhou) Co., Ltd. ("DualityBio", HKEX: 9606.HK) announced today that the